Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

An improved system for the evaluation of antiviral compounds against herpes simplex virus type 2.

Yin S, Li Y, Xia H, Zhao J, Zhang Z, Tang S, Kou Z, Chen J, Yu J, Fan Z, Li T.

J Virol Methods. 2013 May;189(2):317-20. doi: 10.1016/j.jviromet.2013.02.006. Epub 2013 Feb 27.

PMID:
23454799
2.
3.

Effect of resveratrol on herpes simplex virus vaginal infection in the mouse.

Docherty JJ, Fu MM, Hah JM, Sweet TJ, Faith SA, Booth T.

Antiviral Res. 2005 Sep;67(3):155-62.

PMID:
16125258
4.

Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.

Eide K, Moerdyk-Schauwecker M, Stein DA, Bildfell R, Koelle DM, Jin L.

Antivir Ther. 2010;15(8):1141-9. doi: 10.3851/IMP1694.

PMID:
21149921
5.

3-Hydroxyphthaloyl beta-lactoglobulin. IV Antiviral activity in the mouse model of genital herpesvirus infection.

Kokuba H, Aurelian L, Neurath AR.

Antivir Chem Chemother. 1998 Jul;9(4):353-7.

PMID:
9875414
6.
7.
8.
9.

Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy.

Farley N, Bernstein DI, Bravo FJ, Earwood J, Sawtell N, Cardin RD.

Antiviral Res. 2010 May;86(2):188-95. doi: 10.1016/j.antiviral.2010.02.317. Epub 2010 Feb 16.

10.

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH.

Vaccine. 2012 Oct 12;30(46):6541-50. doi: 10.1016/j.vaccine.2012.08.049. Epub 2012 Sep 1.

11.

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.

Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, Brown C, Van Nest G, Stanberry LR.

J Virol. 2002 Nov;76(22):11387-96.

12.

In vivo anti-herpes simplex virus activity of a sulfated derivative of Agaricus brasiliensis mycelial polysaccharide.

Cardozo FT, Larsen IV, Carballo EV, Jose G, Stern RA, Brummel RC, Camelini CM, Rossi MJ, Simões CM, Brandt CR.

Antimicrob Agents Chemother. 2013 Jun;57(6):2541-9. doi: 10.1128/AAC.02250-12. Epub 2013 Mar 18.

13.

Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.

Katsumata K, Chono K, Sudo K, Shimizu Y, Kontani T, Suzuki H.

Molecules. 2011 Aug 25;16(9):7210-23. doi: 10.3390/molecules16097210.

14.

Protective effect of brown Brazilian propolis against acute vaginal lesions caused by herpes simplex virus type 2 in mice: involvement of antioxidant and anti-inflammatory mechanisms.

Sartori G, Pesarico AP, Pinton S, Dobrachinski F, Roman SS, Pauletto F, Rodrigues LC Jr, Prigol M.

Cell Biochem Funct. 2012 Jan;30(1):1-10. doi: 10.1002/cbf.1810. Epub 2011 Oct 24.

PMID:
22025285
15.

Efficacy of orally administered low dose N-methanocarbathymidine against lethal herpes simplex virus type-2 infections of mice.

Quenelle DC, Collins DJ, Rice TL, Rahman A, Glazer R.

Antivir Chem Chemother. 2011 Nov 17;22(3):131-7. doi: 10.3851/IMP1901.

PMID:
22095521
16.

Geldanamycin, a ligand of heat shock protein 90, inhibits herpes simplex virus type 2 replication both in vitro and in vivo.

Li YH, Lu QN, Wang HQ, Tao PZ, Jiang JD.

J Antibiot (Tokyo). 2012 Oct;65(10):509-12. doi: 10.1038/ja.2012.67. Epub 2012 Aug 22.

PMID:
22909975
17.

A 3-O-sulfated heparan sulfate binding peptide preferentially targets herpes simplex virus 2-infected cells.

Ali MM, Karasneh GA, Jarding MJ, Tiwari V, Shukla D.

J Virol. 2012 Jun;86(12):6434-43. doi: 10.1128/JVI.00433-12. Epub 2012 Apr 4.

18.
19.

Observations on recovery from and recurrence of HSV-2 infections in adult mice that were rescued from lethal vaginal infection by antiviral therapy.

Parr EL, Holliday EM, Collard MW, Parr MB.

Arch Virol. 2005 Sep;150(9):1885-902. Epub 2005 Apr 14.

PMID:
15824886
20.
Items per page

Supplemental Content

Write to the Help Desk